Olmutinib-induced palmoplantar keratoderma
Journal
British Journal of Dermatology
Journal Volume
178
Journal Issue
2
Pages
e129-e131
Date Issued
2018
Author(s)
Abstract
olmutinib is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) for the treatment of non-small cell lung cancer (NSCLC), especially for those harboring T790M mutations, the most common reason for other EGFR-TKI resistance. We describe three patients who developed acquired palmoplantar keratoderma (PPK) after taking olmutinib, an adverse event which has not been reported in previous generations of EGFR-TKIs. This article is protected by copyright. All rights reserved.
SDGs
Other Subjects
afatinib; carboplatin; erlotinib; gefitinib; Ki 67 antigen; olmutinib; pemetrexed; antineoplastic agent; epidermal growth factor receptor; olmutinib; piperazine derivative; pyrimidine derivative; acanthosis; adult; aged; case report; chemotherapy; clinical article; dermatitis; disease course; disease exacerbation; drug induced disease; drug withdrawal; exon; female; gene deletion; gene mutation; human; hyperkeratosis; immunohistochemistry; Letter; lung non-small cell carcinoma cell line; middle aged; palmoplantar keratoderma; papillary dermis; parakeratosis; priority journal; skin biopsy; antagonists and inhibitors; chemically induced; drug eruption; lung tumor; male; non small cell lung cancer; palmoplantar keratoderma; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Eruptions; ErbB Receptors; Female; Humans; Keratoderma, Palmoplantar; Lung Neoplasms; Male; Middle Aged; Piperazines; Pyrimidines
Publisher
Blackwell Publishing Ltd
Type
letter